• Keine Ergebnisse gefunden

1Deliveringinnovative solutionsbyconnectingtechnologyand businesstodrivesustainablegrowth08 June 2021 Andreas Fischer (CIO)

N/A
N/A
Protected

Academic year: 2022

Aktie "1Deliveringinnovative solutionsbyconnectingtechnologyand businesstodrivesustainablegrowth08 June 2021 Andreas Fischer (CIO)"

Copied!
10
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Delivering innovative solutions by connecting technology and business to drive sustainable

growth

08 June 2021

Andreas Fischer (CIO)

(2)

Ongoing portfolio transformation

Target: Specialty portfolio with 100% growth businesses

Innovation & Sustainability as growth drivers

€1 bn additional sales from innovation growth fields by 2025

Growing portfolio share of

“Next Generation Solutions”

Ambitious financial targets

EBITDA margin: 18-20%

Cash conversion ratio: >40%

ROCE: 11%

Performance-driven corporate culture

Further drive

gender and cultural diversity

Deliver on efficiency programs in Administration & Operations

As ONE Evonik, innovation is deeply rooted in group strategy Leading beyond chemistry to drive sustainable growth and profitability

LEADING

BEYOND

CHEMISTRY

(3)

The ONE Evonik strategy is reflected in our new RD&I setup

ONE Evonik

Research, Development &

Innovation Regions Executive Board

Divisions

Specialty Additives

Nutrition &

Care

Smart Materials

Performance Materials

Technology &

Infrastructure

Research, Development &

Innovation

R&D Nutrition & Care R&D Resource Efficiency R&D Performance Materials Creavis

Evonik Venture Capital Steering

ONE RD&I ONE Portfolio

- Leverage Synergies ("Speed of Light" - mRNA) - Integrate sustainability in portfolio management by PARC analysis

(4)

Our strategy

with an aligned set of goals contributing to Evonik’s success

Sustainability

Our activities…

We make the best use

of our resources withshared technology platformsand focus on our most promising

projects

We deliver innovative solutions by connecting technology & business to drive sustainable growth

Growth & Profitability Platform Technologies

We create opportunities to achieve our financial target of€1 bn additional sales by 2025 with products of

our six innovation growth fields We develop sustainable solutions

as a key factor in decision-making and key success factor forfuture growth

 Deliver R&D on new product and processes

 Create & grow businesses beyond core

 Recruit and develop new talents

 Steer portfolio and optimize resource allocation

 Manage partnershipswith key customers, startups and universities

 Build reputationas a seal of quality for customers,

(5)

Bundling our biotechnology competencies into one platform Consistent focus on future topics

Process Design Target

Systems

Lab Operations Systems Biotechnology

Microbial Factory Systems In silico

Systems

Process Biotechnology Biotechnology Platform Program & Project Management

 ~200 employees

 > 100 products

 Success Stories

 Gut Health Solutions

 Veramaris

 Biosurfactants

(6)

Creavis

intermediate structure

With Creavis as the dedicated unit for business incubation, Evonik gains an effective lever to foster its growth ambitions

Jul 1, 2020

Previous Creavis

New Business Development Nutrition & Care

NC-NBD

Innovation Networks New Growth Businesses Resource Efficiency RE-SG-NGB

Networks Transfer of

Marl Biotech labs to NC R&D

Transfer of Membrane and AM projects to SM-HP R&D

Go-live

+ Revision of the Creavis project portfolio Dec 1, 2020

(7)

Venture Capital activities driven by strategic goals and financial returns

Powerful partner fostering growth opportunities with entrepreneurs to expand boundaries

 Direct investments in global innovation leaders with disruptive technologies and business models

 Selective fund investments in key geographies and Evonik areas of interest

 Syndication with top tier (corporate) venture capital funds

 Investments in early-to-growth and later-stage companies(sweet spot lying in Series A & B rounds) with established proof of concept (sweet spot at Technology Readiness Level 5 to 6)

 Total investment of up to €15 million over the lifecycle of the investment

 Maintaining minority shareholding, typically between 10 and 20%

 Active partner that often serves on boards

Investment principles

(8)

Leading in Innovation – Growth fields and sales target On track to achieve target of >€1 bn sales from innovation

Advanced Food Ingredients

Additive Manufacturing Sustainable Nutrition

Cosmetic

Solutions Membranes Health Care

Solutions

Sizeable sales base established in all growth fields

Above-average margin contribution 2015 2016 2017 2018 2019 2020 2025

~350 From “zero” to ~€350 m in just 5 years

Innovation Growth Fields Sales contribution Innovation Growth Fields

(9)

Next Generation Solutions addressing Evonik’s “Sustainability Focus Areas”

Directly linked to UN SDGs, Innovation Growth Fields and future programs

Membranes for gas separation Fully integrated, membrane-based hybrid technology to extract

hydrogen from natural gas pipelines.

Silicones for UV curable labels Enable customers to reduce 40% of material consumption and conserve resources (400t CO2)

Rhamnolipids for cleaning Based on deforestation-free raw materials & 100% renewable energy for production.

LNPs for mRNA encapsulation Targeted drug delivery to fight diseases such as COVID 19 with the new mRNA technology.

Linerless labels Biosurfactants Drug Delivery Systems

Fight Climate Change Drive Circularity Safeguard Ecosystems Ensure Health & Well-Being Our four “Sustainability Focus Areas”

Membranes

(10)

Referenzen

ÄHNLICHE DOKUMENTE

▪ Price increases of ~€450 m in Q3 (yoy) compensating higher variable costs (mainly raw materials, energy, logistics) Specialty Additives & Smart Materials. ▪ Ramp-up of

Specialty Additives Nutrition & Care Smart Materials Performance Materials.. Broad spectrum of additives and versatile crosslinkers

▪ Global water management system: development of site-specific action plans within Evonik Group regarding water stress. ▪ Oxidation agents, waste

Structural growth drivers well intact across all three growth divisions – sustainability as common theme Continued strong cash generation: On track to extend 40% cash conversion

▪ Strong yoy earnings growth and clear margin improvement to 18.3%, driven by shift to system solutions and active cost management. ▪ Health & Care: Q1 with 7% sales growth due

Specialty businesses: Specialty Additives, Smart Materials, Health & Care (excl. Animal Nutrition & Performance Materials). 1: Calculation for operating businesses

Specialty Additives Nutrition & Care Smart Materials Performance Materials. Broad

▪ Animal Nutrition: Healthy business performance continuing in Q3; higher raw material costs to be compensated by successfully implemented own price increases going